These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. A method to determine the optimal intensity of oral anticoagulant therapy. Rosendaal FR; Cannegieter SC; van der Meer FJ; Briët E Thromb Haemost; 1993 Mar; 69(3):236-9. PubMed ID: 8470047 [TBL] [Abstract][Full Text] [Related]
67. [Ambulatory follow-up in oral anticoagulation: recommendations for clinical practice]. Christen Y; Perrier A; de Moerloose P Schweiz Med Wochenschr; 1996 Mar; 126(12):471-6. PubMed ID: 8650511 [TBL] [Abstract][Full Text] [Related]
69. [Oral anticoagulation therapy in the primary care setting]. Vinker S; Nakar S; Finkel S; Nir E; Hyam E Harefuah; 1997 Jun; 132(11):753-6, 824, 823. PubMed ID: 9223814 [TBL] [Abstract][Full Text] [Related]
70. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. Oake N; Fergusson DA; Forster AJ; van Walraven C CMAJ; 2007 May; 176(11):1589-94. PubMed ID: 17515585 [TBL] [Abstract][Full Text] [Related]
71. Hospitalized women experiencing an episode of excessive oral anticoagulation had a higher bleeding risk than men. Cosma Rochat M; Waeber G; Wasserfallen JB; Nakov K; Aujesky D J Womens Health (Larchmt); 2009 Mar; 18(3):321-6. PubMed ID: 19281315 [TBL] [Abstract][Full Text] [Related]
72. [The causes of intracranial hemorrhagic complications induced by antivitamins K]. Lacroix P; Portefaix O; Boucher M; Ramiandrisoa H; Dumas M; Ravon R; Christides C; Laskar M Arch Mal Coeur Vaiss; 1994 Dec; 87(12):1715-9. PubMed ID: 7786112 [TBL] [Abstract][Full Text] [Related]
73. Improved therapeutic safety of oral anticoagulant therapy in Germany: the Saarland model. Mörsdorf S; Leipnitz G; Pindur G; Schenk JF; Erdlenbruch W; Krischek B; Wenzel E Semin Thromb Hemost; 1999; 25(1):49-55. PubMed ID: 10327221 [TBL] [Abstract][Full Text] [Related]
74. [Pharmacoepidemiologic investigations about the interactions between oral anticoagulants and other drugs in patients with hemostasis disorders]. Apostoae F; Tarţău L; Cimpoeşu D; Lupuşoru CE Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1155-61. PubMed ID: 22276463 [TBL] [Abstract][Full Text] [Related]
75. Quality of oral anticoagulant control and treatment in Sweden. Duration of Anticoagulation (DURAC) Trial Study Group. Schulman S J Intern Med; 1994 Aug; 236(2):143-52. PubMed ID: 8046313 [TBL] [Abstract][Full Text] [Related]
76. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. Sadanaga T; Sadanaga M; Ogawa S J Am Coll Cardiol; 2010 May; 55(20):2225-31. PubMed ID: 20466203 [TBL] [Abstract][Full Text] [Related]
77. [Clinical experiences with anticoagulant long term treatment of predominantly cardiologic patients]. Kubicek F; Praschl E Wien Klin Wochenschr; 1968 Nov; 80(44):813-9. PubMed ID: 4974107 [No Abstract] [Full Text] [Related]
78. [Is optimal anticoagulation possible in ambulatory practice? Report on a retrospective 5-year study of a cardiology practice]. von Bertrab R Schweiz Med Wochenschr; 1985 Aug; 115(31-32):1092-105. PubMed ID: 4048907 [TBL] [Abstract][Full Text] [Related]
79. [Morbidity and mortality in patients treated with oral anticoagulants]. Navarro JL; Cesar JM; Fernández MA; Fontcuberta J; Reverter JC; Gol-Freixa J Rev Esp Cardiol; 2007 Dec; 60(12):1226-32. PubMed ID: 18082087 [TBL] [Abstract][Full Text] [Related]
80. Oral anticoagulation in surgical procedures: risks and recommendations. Torn M; Rosendaal FR Br J Haematol; 2003 Nov; 123(4):676-82. PubMed ID: 14616972 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]